all updates

Press Releases

GvHD Hub Press Release Q1: The Gvhd Hub in Q1 2022: Boosting Levels Of Knowledge In The Graft-Versus-Host Disease Setting Through Key Updates And Congress Coverage

April 13, 2022

The GvHD Hub, run by Scientific Education Support (SES) in partnership with the European LeukemiaNet (ELN), is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in graft-versus-host disease (GvHD). The GvHD Hub remains dedicated to bringing you the latest information regarding COVID-19 and its implications in patients undergoing hematopoietic stem cell transplantation, as well as addressing the unmet medical needs in the field. 

During Q1 of 2022, the GvHD Hub attended the 48th Annual Meeting of the EBMT, which was held in a virtual format. For the event, we provided live coverage across multiple social media channels, including Twitter, for which a collection of all activity has been captured in a Twitter Moment. Our main areas of interest included the treatment of chronic GvHD, managing the multiple facets of GvHD treatment, and the tools available for risk stratification of GvHD. The social coverage for the congress helped generate over 39,000 impressions on our social channels and contributed towards over 3,400 website users during the quarter. The metrics seen during Q1 demonstrate the impact the hub has in the GvHD community; therefore, we will continue to provide our audience with the latest updates and insights in GvHD. During Q1, we also published a visual abstract that represents considerations in the treatment of acute GvHD. 

Reviewing the GvHD Hub’s impact this quarter, Sam Larkin, GvHD Hub’s Content Lead at Scientific Education Support, said: 

“During this quarter, the GvHD Hub provided live session coverage for the 48th Annual Meeting of the EBMT, maintaining an online presence to facilitate the dissemination of key updates and breakthroughs in GvHD worldwide.  

“As part of our commitment to continuously enhance the hub’s user experience, we also introduced a new digital innovation with the addition of Google Translate to the hub. As a result, the hub’s content can now be translated into 100 different languages, which will further enhance our global coverage and help us reach new audiences. 

“The GvHD Hub is supported by Incyte , Novartis , Syndax , Kadmon and BMS; we remain grateful for their invaluable support. We would also like to thank the GvHD Hub Steering Committee for their continued guidance.” 


For more information on the GvHD Hub, please visit

For media enquiries or to explore collaboration opportunities, please contact or


About graft-versus-host disease (GvHD) 

GvHD is a common complication of allogeneic hematopoietic stem cell transplantation and is a major cause of posttransplant mortality and morbidity. It is caused by immune incompatibility between the graft (donor) and recipient tissues. The graft cells recognize the recipient tissues as foreign and mount an immune response against them. 

About the GvHD Hub 

The GvHD Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education on GvHD. Our aim is to enhance knowledge of GvHD through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management. 

The GvHD Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the GvHD Hub supports HCPs worldwide. 

Founded in partnership with the European LeukemiaNet in 2018, the GvHD Hub is guided by an international steering committee of experts in the field of GvHD. The steering committee meet regularly to discuss the performance of the GvHD Hub and to devise action plans on how best to support the GvHD community and address any unmet educational needs. 

GvHD Hub supporters 

Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content. 

  • Incyte 
  • Novartis 
  • Syndax 
  • Kadmon 
  • BMS 

If you are interested in becoming an GvHD Hub supporter, please contact

About Scientific Education Support (SES) 

SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs. 

SES already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the ALL Hub, AML Hub, Lymphoma Hub, MDS Hub, Multiple Myeloma Hub, and MPN Hub

About the European LeukemiaNet 

220 participating centers in 44 countries with more than 1000 researchers and clinicians are cooperating in the European LeukemiaNet. The objective is to integrate the about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a network promoting cooperative research for curing leukemia. 

Sign Up For Our Monthly Newsletter

Looking to receive the latest news, project updates, and new offerings?